Gilead Sciences has disclosed a strategic partnership with Genesis Therapeutics to create innovative small molecule therapies that leverage artificial intelligence. The partnership will utilize the Genesis AI platform, GEMS (Genesis Exploration of Molecular Space), to generate and optimize molecules for multiple therapeutic targets that Gilead has selected. The collaboration emphasizes the increasing significance of AI in the expedition of drug discovery, particularly for diseases that are challenging to target. “The use of generative AI in drug development, enabled by people, science and other new technology, has shown potential to accelerate the discovery of molecules for challenging targets,” stated Flavius Martin, MD, Executive Vice President of Research at Gilead Sciences.
Genesis will receive a $35 million advance payment as part of the agreement to support the development of therapies that first target three specific areas. For an additional fee, Gilead maintains the capacity to propose additional targets. Gilead's earned per share (EPS) in 2024 are anticipated to decline by approximately $0.02 as a result of the collaboration. Genesis Therapeutics is at the forefront of AI-based drug discovery, while Gilead Sciences is dedicated to the development of innovative medications that will enhance global health outcomes. The joint endeavor of the organizations is to leverage AI to expedite the delivery of more effective therapies.
